Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
After 14 months of nivolumab administration, radiographic and serological (β-HCG) stability was observed in that patient.
“After 14 months of nivolumab administration, radiographic and serological (β-HCG) stability was observed [48].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [48]
A durable response to nivolumab was described in a patient with poor risk metastatic choriocarcinoma.
“Moreover, a durable response to nivolumab was described in a patient with poor risk metastatic choriocarcinoma in a case report by Chi et al. [48].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [48]
Cites
Zschäbitz, S., Lasitschka, F., Hadaschik, B., Hofheinz, R.-D., Jentsch-Ullrich, K., Grüner, M., Jäger, D., & Grüllich, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.033 · Cited by 75 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Phase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81 · see citing works
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11 · see citing works
“Moreover, a durable response to nivolumab was described in a patient with poor risk metastatic choriocarcinoma in a case report by Chi et al. [48].”
Background
- Authors
- Chi, E. A., & Schweizer, M. T.
- Affiliations
- University of Washington (US)
- Corresponding author
- Schweizer, Michael T.
- Venue
- Clinical Genitourinary Cancer
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 15
- Issue
- 5
- Pages
- e855-e857
- ISSN
- 1558-7673 (ISSN-L)
- OpenAlex
- W2606544123
- Cited by
- 37
- References
- 1
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 3 · 2017: 1
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Genitourinary Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint blockade, non-seminoma, platinum-refractory disease, metastatic germ cell tumors, durable response, high-dose chemotherapy, autologous stem cell transplantation, immunotherapy
- MeSH terms
- Nivolumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Humans, Ifosfamide, Male, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Podophyllotoxin, Testicular Neoplasms, Treatment Outcome, Off-Label Use, Watchful Waiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
